Crohn’s Disease Market: Insights, Treatment, Market Drivers, Market Barriers, and Report Scope 2032

DelveInsight’s Crohn’s Disease Market Insights report provides a thorough understanding of current treatment practices, emerging Crohn’s Disease market share of the individual therapies, current and forecasted Crohn’s Disease Market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Some of the key highlights of the Crohn’s Disease Market Report

Population-based cohort studies have demonstrated that up to 30% of patients with CD have evidence of bowel damage at diagnosis, and half of these patients require surgery in the 20 years following the diagnosis.
The disease can occur at any age and is more prevalent among adolescents and young adults between the ages of 15 and 35.
Crohn’s disease is more frequent in women than men, as estimated by the Centers for Disease Control and Prevention.
Crohn’s disease market companies are included like UCB, Millennium Pharmaceuticals, and many others.
Crohn’s disease drugs are included like CIMZIA (certolizumab pegol), ENTYVIO (vedolizumab), and many others.

 

Do you know how the Crohn’s disease market will grow by 2030? Click to get in-depth detail of Crohn’s disease Market Outlook

 

Crohn’s Disease Overview

Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus. Additionally, ulcerative colitis, an IBD that causes long-lasting inflammation and ulcers (sores) in your digestive tract, is limited to the colon, also called the large intestine.

 

Crohn’s Disease Causes

In Crohn’s disease, the immune system mistakenly attacks healthy bacteria in the GI tract. Chronic inflammation causes thickening of the intestinal wall, which triggers the symptoms. Several factors have been implicated in causing Crohn’s disease, including a dysregulated immune system, an altered microbiota, genetic susceptibility, and environmental factors, but its cause unknown. Between 5% and 20% of people who have an IBD have a first-degree relative with one. The risk is higher in Crohn’s than ulcerative colitis, and higher when both parents are affected (as per Crohn’s & Colitis Foundation of America).

 

Crohn’s Disease Treatment

The standardized approved evidence-based therapies for the treatment of Crohn’s disease include infliximab (Remicade; Janssen Biotech), adalimumab (Humira; AbbVie), certolizumab Pegol (Cimzia; UCB), natalizumab (Tysabri; Biogen), vedolizumab (Entyvio; Millennium Pharmaceuticals), and Ustekinumab (Stelara; Janssen Biotech). These therapies have been approved for moderate to severe Crohn’s disease.

 

 

Crohn’s disease Market Drivers

Increase in research activities
Increasing disease prevalence
The surge in a number of clinical studies

 

Crohn’s disease Market Barriers

Treatment costs
Need for novel therapeutics
Entry of biosimilars

 

Crohn’s disease Market Report Scope

The report covers the descriptive overview of Crohn’s Disease (CD), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
Comprehensive insight has been provided into the Crohn’s Disease (CD) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Crohn’s Disease (CD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Crohn’s Disease (CD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Crohn’s Disease (CD) market

 

Crohn’s disease Market Companies

UCB
Millennium Pharmaceuticals
And many others

 

Crohn’s disease Drugs

CIMZIA (certolizumab pegol)
ENTYVIO (vedolizumab)
And many others

 

Get detailed information about Therapies @ Crohn’s disease Therapies

 

Table of Content

Key Insights
Executive Summary of Crohn’s Disease (CD)
Competitive Intelligence Analysis for Crohn’s Disease (CD)
Crohn’s Disease (CD): Market Overview at a Glance
Crohn’s Disease (CD): Disease Background and Overview
Patient Journey
Crohn’s Disease (CD) Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Unmet Needs
Key Endpoints of Crohn’s Disease (CD) Treatment
Marketed Products
Emerging Therapies
Crohn’s Disease (CD): Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview of Crohn’s Disease (CD)
KOL Views
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

 

 

About DelveInsight

DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Yash

info@delveinsight.com

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/